ILMN

Illumina's stock has been impacted by stronger-than-expected earnings for the first quarter of 2026, with revenue and EPS surpassing analyst forecasts, leading to a stock rise. The company posted a non-GAAP EPS of $1.15 and revenue of $1.09 billion, driven by strong demand for sequencing consumables and instruments, particularly in clinical applications, and the robust uptake of the NovaSeq X platform. Management raised its full-year 2026 revenue and adjusted EPS guidance, approved a new $1.5 billion share repurchase program, and completed the acquisition of SomaLogic.